Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Hologic, Inc is a medical instruments & supplies business based in the US. Hologic shares (HOLX) are listed on the NASDAQ and all prices are listed in US Dollars. Hologic employs 5,814 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$60.72|
|52-week range||$56.81 - $85.00|
|50-day moving average||$67.40|
|200-day moving average||$70.90|
|Wall St. target price||$83.58|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$7.81|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-10.32%|
|3 months (2021-04-30)||-7.37%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Valuing Hologic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hologic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hologic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Hologic shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hologic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7227. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hologic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hologic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 billion.
The EBITDA is a measure of a Hologic's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5.7 billion|
|Operating margin TTM||47.45%|
|Gross profit TTM||$2.5 billion|
|Return on assets TTM||21.82%|
|Return on equity TTM||66.32%|
|Market capitalisation||$18.7 billion|
TTM: trailing 12 months
There are currently 6.2 million Hologic shares held short by investors – that's known as Hologic's "short interest". This figure is 4.8% down from 6.5 million last month.
There are a few different ways that this level of interest in shorting Hologic shares can be evaluated.
Hologic's "short interest ratio" (SIR) is the quantity of Hologic shares currently shorted divided by the average quantity of Hologic shares traded daily (recently around 2.4 million). Hologic's SIR currently stands at 2.57. In other words for every 100,000 Hologic shares traded daily on the market, roughly 2570 shares are currently held short.
However Hologic's short interest can also be evaluated against the total number of Hologic shares, or, against the total number of tradable Hologic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hologic's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Hologic shares in existence, roughly 20 shares are currently held short) or 0.0244% of the tradable shares (for every 100,000 tradable Hologic shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hologic.
Find out more about how you can short Hologic stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hologic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hologic's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 58th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Hologic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.95/100
Hologic's environmental score of 2.95 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 11.28/100
Hologic's social score of 11.28 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.88/100
Hologic's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Hologic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Hologic scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Hologic has, for the most part, managed to keep its nose clean.
|Total ESG score||28.6|
|Total ESG percentile||58.02|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||2|
We're not expecting Hologic to pay a dividend over the next 12 months.
Hologic's shares were split on a 2:1 basis on 2 April 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Hologic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Hologic shares which in turn could have impacted Hologic's share price.
Over the last 12 months, Hologic's shares have ranged in value from as little as $56.81 up to $85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hologic's is 1.1746. This would suggest that Hologic's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.